MedX Announces Intention to Seek Acceptance for Extension of Warrants

MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that it is making an Application to the TSX-V for Acceptance of the proposed extension of the Expiration Dates of a series of Warrants issued in April/May, 2020 in connection with a Private Placement completed at that time. Subject to, and conditional on Acceptance by the TSX-V, the Company will extend the Expiration dates of a total of 14,995,472 share purchase warrants (“Warrants”) and 569,760 brokers warrants (“Brokers Warrants”) from their respective Expiration dates of April 22, 27 and 29 and May 13, 2022, to December 31, 2023. Each of the Warrants is exercisable to purchase one common share from the Treasury of MedX at $0.20, and each of the Brokers Warrants is exercisable to purchase a broker’s unit from the Company at $0.12, with each brokers unit comprising one common share and one share purchase warrant exercisable to purchase one additional common share at $0.20.

About MedX Health Corp.

MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy^® on DermSecure^® telemedicine platform, utilizing its SIAscopy^® technology. SIAscopy^® is also imbedded in its products SIAMETRICS^®, SIMSYS^®, and MoleMate^®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS^®, SIMSYS^®, and MoleMate^® include hand-held devices that use patented technology utilizing light and its remittance to view suspicious moles and lesions up to 2mm beneath in a pain-free, non-invasive manner. Its patented software then creates real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union, Brazil and Turkey. For more information, visit www.medxhealth.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220314005784/en/

Bill Mitoulas, Investor Relations
MedX Health Corp.
[email protected]
+1-416-479-9547